Cellectis bioresearch launches Compact TALEN™ the next generation of TAL effector nucleases
Published on September 23, 2013
Paris (France), September 23, 2013 - Cellectis bioresearch, a subsidiary of Cellectis Group (Alternext: ALCLS), the genome engineering specialist, announces the launch of a monomeric Compact TALEN™, that allows efficient transfection and genome editing in sensitive cells.
Transfection of sensitive cells such as primary cells, plant cells and iPS cells is the major limitation for efficient genome editing. To breakdown this barrier, Cellectis scientists have developed a monomeric TALEN™, distributed under the name Compact TALEN™. In contrast to Custom TALEN™, the monomeric Compact TALEN™ requires the expression of only one DNA or RNA molecule to be active. This exquisite property, not only ease DNA/RNA cell transfection but offers a tremendous advantage to scientist who have to use viral shuttles for vectorization. The Cellectis Group is the first in its sector to develop and market such a tool. This technology greatly simplifies the design and synthesis as well as the therapeutic delivery of nucleases.
This new product based on Cellectis’ proprietary TAL effector nuclease technology makes it possible to target specific DNA segments using just a single molecule, as shown in the innovative study on ultra-precise Compact TALEN™ published in the scientific journal Nature Communications:
Nat Commun. 2013;4:1762. doi: 10.1038/ncomms2782.
Compact designer TALENs for efficient genome engineering.
Beurdeley M, Bietz F, Li J, Thomas S, Stoddard T, Juillerat A, Zhang F, Voytas DF, Duchateau P, Silva GH.
Cellectis, Research and Development
Compact TALEN™ constitutes a breakthrough in the fields of genome engineering and synthetic biology. This technology is covered by an international patent application published under WO 2012/138927.
For further information please visit our website www.cellectis-bioresearch.com